Business
Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy. With HT-001 advancing globally, HT-KIT achieving key validation milestones, the expansion of its treasury reserve strategy to include Bitcoin, Ethereum, and Solana, and the advancement of its VA obesity program, management emphasized that Hoth is operating from the strongest position
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy. With HT-001 advancing globally, HT-KIT achieving key validation milestones, the expansion of its treasury reserve strategy to include Bitcoin, Ethereum, and Solana, and the advancement of its VA obesity program, management emphasized that Hoth is operating from the strongest position in its history.","length":567,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hoth Therapeutics Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hoth Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":68,"url":"https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r2Ptel_Ut1tf_dA2SUFY0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a168928171a9653a66d38f6c5e666beb","width":400,"height":68}},"href":"https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Key Developments Driving Momentum","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"HT-001: Advancing GloballyHoth has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for EGFR inhibitor-induced skin toxicities. Pending approval, European patient enrollment is expected to begin in early 2026, complementing active enrollment already underway in the U.S.","length":382,"tagName":"p"}]},{"val":[{"type":"text","content":"HT-KIT: Achieving Preclinical MilestonesThe Company successfully completed the Good Laboratory Practice (GLP) bioanalytical phase for HT-KIT, exceeding internationally recognized regulatory thresholds. This achievement supports advancement into formal toxicology studies and regulatory submission, reinforcing the strength and depth of Hoth's pipeline.","length":357,"tagName":"p"}]},{"val":[{"type":"text","content":"VA Obesity ProgramHoth is advancing its obesity initiative in partnership with the U.S. Department of V...